EMD Millipore Partners with The Breast Cancer Research Foundation®

Company and Products Go “Pink” to Support Critical Innovative Research

BILLERICA, Mass.--(BUSINESS WIRE)-- EMD Millipore, the Life Science division of Merck KGaA* of Germany, today announced it has partnered with The Breast Cancer Research Foundation® (BCRF). Through this partnership, EMD Millipore will allocate a portion of product sales and a $20,000 grant to fund the organization’s research efforts. The Company will also feature the BCRF “pink” logo on select products and packaging to promote breast cancer awareness.

“As many of our products are used to research and combat cancer, we felt it was important to partner with a leading organization also dedicated to this fight, “says John Sweeney, Vice President, Life Sciences. “We are especially proud to support The Breast Cancer Research Foundation® during Breast Cancer Awareness Month and believe our combined resources may further advances towards combating this deadly disease.”

From today through September 30, 2011, EMD Millipore will donate a portion of proceeds from the sale of Guava® Flow Cytometry EasyCyte™ systems to BCRF. The company will donate $300 or $800 for each instrument sold to this charity. This donation combined with the $20,000 grant will support over 170 global BCRF researchers committed to breast cancer prevention and ultimately, a cure.

Flow cytometry is a technique used by scientists to measure physical and/or chemical changes within individual cells. These changes may occur as a consequence of many important factors, including cancer development.

About EMD Millipore

EMD Millipore is the Life Science division of Merck KGaA of Germany and offers a broad range of innovative, performance products, services and business relationships that enable our customers' success in research, development and production of biotech and pharmaceutical drug therapies. Through dedicated collaboration on new scientific and engineering insights, and as one of the top three R&D investors in the Life Science Tools industry, EMD Millipore serves as a strategic partner to customers and helps advance the promise of life science.

Headquartered in Billerica, Massachusetts, the division has around 10,000 employees, operations in 64 countries and pro forma 2009 revenues of $2.9 billion.

EMD Millipore is known as Merck Millipore outside of the U.S. and Canada.

Millipore and Guava are registered and EasyCyte is a trademark of Millipore Corporation.

*Merck KGaA or Merck shall mean Merck KGaA, Darmstadt, Germany

About BCRF

The Breast Cancer Research Foundation® was founded in 1993 by Evelyn H. Lauder as an independent, not-for-profit organization dedicated to funding innovative clinical and translational research. In October 2010, BCRF will award $33 million to 172 scientists across the United States, Canada, Latin America, Europe, the Middle East, and Australia. Currently, more than 90 cents of each dollar donated to the Foundation goes directly to breast cancer research and awareness programs. And the American Institute of Philanthropy has awarded the Foundation its highest possible rating of A+. BCRF is the only breast cancer organization to receive this accolade, and is the only cancer organization to currently hold this ranking. For more information about BCRF, visit www.bcrfcure.org.

Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6484148&lang=en



CONTACT:

EMD Millipore
Karen Marinella Hall, 978-715-1567

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Women  Technology  Hardware  Health  Biotechnology  Oncology  Manufacturing  Chemicals/Plastics  Philanthropy  Environment  Research  Consumer  Science  Foundation  Fund Raising  Men

MEDIA:

Logo
 Logo

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.